Visual field severity indices demonstrate dose-dependent visual loss from Vigabatrin therapy

Miriam Conway, Robert P. Cubbidge, Sarah L. Hosking

Research output: Contribution to journalArticle

Abstract

Purpose: The aims of this study were to develop an algorithm to accurately quantify Vigabatrin (VGB)-induced central visual field loss and to investigate the relationship between visual field loss and maximum daily dose, cumulative dose and duration of dose.
Methods: The sample comprised 31 patients (mean age 37.9 years; SD 14.4 years) diagnosed with epilepsy and exposed to VGB. Each participant underwent standard automated static visual field examination of the central visual field. Central visual field loss was determined using continuous scales quantifying severity in terms of area and depth of defect and additionally by symmetry of defect between the two eyes. A simultaneous multiple regression model was used to explore the relationship between these visual field parameters and the drug predictor variables.
Results: The regression model indicated that maximum VGB dose was the only factor to be significantly correlated with individual eye severity (right eye: p = 0.020; left eye: p = 0.012) and symmetry of visual field defect (p = 0.024).
Conclusions: Maximum daily dose was the single most reliable indicator of those patients likely to exhibit visual field defects due to VGB. These findings suggest that high maximum dose is more likely to result in visual field defects than high cumulative doses or those of long duration.
LanguageEnglish
Pages108-116
Number of pages9
JournalEpilepsia
Volume49
Issue number1
Early online date7 Aug 2007
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Vigabatrin
Visual Fields
Therapeutics
Epilepsy

Keywords

  • epilepsy
  • vigabatrin
  • visual field loss
  • maximum daily dose
  • quantitative

Cite this

@article{3c1670bb6d2546cb82ecd06af4acdc17,
title = "Visual field severity indices demonstrate dose-dependent visual loss from Vigabatrin therapy",
abstract = "Purpose: The aims of this study were to develop an algorithm to accurately quantify Vigabatrin (VGB)-induced central visual field loss and to investigate the relationship between visual field loss and maximum daily dose, cumulative dose and duration of dose. Methods: The sample comprised 31 patients (mean age 37.9 years; SD 14.4 years) diagnosed with epilepsy and exposed to VGB. Each participant underwent standard automated static visual field examination of the central visual field. Central visual field loss was determined using continuous scales quantifying severity in terms of area and depth of defect and additionally by symmetry of defect between the two eyes. A simultaneous multiple regression model was used to explore the relationship between these visual field parameters and the drug predictor variables. Results: The regression model indicated that maximum VGB dose was the only factor to be significantly correlated with individual eye severity (right eye: p = 0.020; left eye: p = 0.012) and symmetry of visual field defect (p = 0.024). Conclusions: Maximum daily dose was the single most reliable indicator of those patients likely to exhibit visual field defects due to VGB. These findings suggest that high maximum dose is more likely to result in visual field defects than high cumulative doses or those of long duration.",
keywords = "epilepsy, vigabatrin, visual field loss, maximum daily dose, quantitative",
author = "Miriam Conway and Cubbidge, {Robert P.} and Hosking, {Sarah L.}",
year = "2008",
month = "1",
doi = "10.1111/j.1528-1167.2007.01249.x",
language = "English",
volume = "49",
pages = "108--116",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley",
number = "1",

}

Visual field severity indices demonstrate dose-dependent visual loss from Vigabatrin therapy. / Conway, Miriam; Cubbidge, Robert P.; Hosking, Sarah L.

In: Epilepsia, Vol. 49, No. 1, 01.2008, p. 108-116.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Visual field severity indices demonstrate dose-dependent visual loss from Vigabatrin therapy

AU - Conway, Miriam

AU - Cubbidge, Robert P.

AU - Hosking, Sarah L.

PY - 2008/1

Y1 - 2008/1

N2 - Purpose: The aims of this study were to develop an algorithm to accurately quantify Vigabatrin (VGB)-induced central visual field loss and to investigate the relationship between visual field loss and maximum daily dose, cumulative dose and duration of dose. Methods: The sample comprised 31 patients (mean age 37.9 years; SD 14.4 years) diagnosed with epilepsy and exposed to VGB. Each participant underwent standard automated static visual field examination of the central visual field. Central visual field loss was determined using continuous scales quantifying severity in terms of area and depth of defect and additionally by symmetry of defect between the two eyes. A simultaneous multiple regression model was used to explore the relationship between these visual field parameters and the drug predictor variables. Results: The regression model indicated that maximum VGB dose was the only factor to be significantly correlated with individual eye severity (right eye: p = 0.020; left eye: p = 0.012) and symmetry of visual field defect (p = 0.024). Conclusions: Maximum daily dose was the single most reliable indicator of those patients likely to exhibit visual field defects due to VGB. These findings suggest that high maximum dose is more likely to result in visual field defects than high cumulative doses or those of long duration.

AB - Purpose: The aims of this study were to develop an algorithm to accurately quantify Vigabatrin (VGB)-induced central visual field loss and to investigate the relationship between visual field loss and maximum daily dose, cumulative dose and duration of dose. Methods: The sample comprised 31 patients (mean age 37.9 years; SD 14.4 years) diagnosed with epilepsy and exposed to VGB. Each participant underwent standard automated static visual field examination of the central visual field. Central visual field loss was determined using continuous scales quantifying severity in terms of area and depth of defect and additionally by symmetry of defect between the two eyes. A simultaneous multiple regression model was used to explore the relationship between these visual field parameters and the drug predictor variables. Results: The regression model indicated that maximum VGB dose was the only factor to be significantly correlated with individual eye severity (right eye: p = 0.020; left eye: p = 0.012) and symmetry of visual field defect (p = 0.024). Conclusions: Maximum daily dose was the single most reliable indicator of those patients likely to exhibit visual field defects due to VGB. These findings suggest that high maximum dose is more likely to result in visual field defects than high cumulative doses or those of long duration.

KW - epilepsy

KW - vigabatrin

KW - visual field loss

KW - maximum daily dose

KW - quantitative

UR - http://www.scopus.com/inward/record.url?scp=37549068143&partnerID=8YFLogxK

UR - http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2007.01249.x/abstract

U2 - 10.1111/j.1528-1167.2007.01249.x

DO - 10.1111/j.1528-1167.2007.01249.x

M3 - Article

VL - 49

SP - 108

EP - 116

JO - Epilepsia

T2 - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 1

ER -